<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="FUSIDIC ACID" rxcui="4608">
<ATC code="D06AX01" />
<ATC code="D09AA02" />
<ATC code="J01XC01" />
<ATC code="S01AA13" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the fusidic acid due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<CLASS name="VASOCONSTRICTOR ALKALOIDS OF ERGOT OF RYE" code="N02CA0-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the vasoconstrictor alkaloid of ergot of rye due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="ALFUZOSIN" rxcui="17300">
<ATC code="G04CA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the alfuzosin due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="AMIODARONE" rxcui="703">
<ATC code="C01BD01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the amiodarone due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="ATORVASTATIN" rxcui="83367">
<ATC code="C10AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the atorvastatin due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="COLCHICINE" rxcui="2683">
<ATC code="M04AC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the colchicine due to decrease of its hepatic metabolism by the bitherapy.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>with patients having renal and/or hepatic insufficiency</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="ETHINYLESTRADIOL" rxcui="4124">
<ATC code="G03AA15" />
<ATC code="G03AB07" />
<ATC code="G03AA09" />
<ATC code="G03AB05" />
<ATC code="G03AA12" />
<ATC code="G03CA01" />
<ATC code="L02AA03" />
<ATC code="G03AA01" />
<ATC code="G03AA10" />
<ATC code="G03AB06" />
<ATC code="G03AA07" />
<ATC code="G03AB03" />
<ATC code="G03AA03" />
<ATC code="G03AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatotoxicity</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<CLASS name="ENZYMATIC INDUCERS" code="N03-J05-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the bitherapy due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<CLASS name="STRONG INHIBITORS OF CYP3A4" code="J02-J05" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the bitherapy due to decrease of its hepatic metabolism by the inhibitor</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>-except with the ritonavir</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the midazolam due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="PIMOZIDE" rxcui="8331">
<ATC code="N05AG02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the pimozide due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quetiapine due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
<ATC code="C01BA51" />
<ATC code="C01BA71" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quinidine due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="SILDENAFIL" rxcui="136411">
<ATC code="G04BE03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the sildenafil due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the simvastatin due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>388-OMBITASVIR + PARITAPREVIR.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the ticagrelor due to decrease of its hepatic metabolism by the bitherapy</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
